# A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults

> **NCT07013097** · PHASE1 · RECRUITING · sponsor: **Prime Gene Therapeutics Co., Ltd.** · enrollment: 52 (estimated)

## Conditions studied

- Lichen Simplex Chronicus

## Interventions

- **DRUG:** PG-033
- **DRUG:** PG-033 placebo comparator

## Key facts

- **NCT ID:** NCT07013097
- **Lead sponsor:** Prime Gene Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-23
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2025-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07013097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07013097, "A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07013097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*